european technology platform nanomedicine 106/12/2006 paul smit, philips paul smit november 2006

EUROPEAN TECHNOLOGY PLATFORMNANOMEDICINE

Paul Smit, Philips 1 06/12/2006

Paul Smit

November 2006



Healthcare Expenditures will grow from ~9% of worldwide GDP to ~11% in 2015

The Americas makes up 56%of the worldwide spend

Source: Medistat

0%

2%

4%

6%

8%

10%

1950 2005 2015

Source: WHO, Philips Internal Analysis

Healthcare is the world’s largest service sector

30%

2%

8%

1% 5%

54%

Americas

Europe, Mid-East,Africa

China/HK

J apan

India

Rest of Asia

Worldwide Healthcare Expenditure: US$3,834 bln in 2004



Key Challenges in Medicine

• Translating breakthroughs in understanding of disease into preventive medicine

• How to increase productivity dramatically

• How to align reimbursement with better outcome and efficiency

• How to design affordable healthcare for the bottom-of-the-pyramid

• How to reap the benefits of healthcare while reducing the ineffeciencies

• largest factor of a country’s economic growth



NanoMedicine is about early diagnosis and “preventive” treatment

Through screening and early diagnosis find disease early and intervene early

Symptoms

time

Clinical Symptoms

TreatmentFollow-upDiagnosisScreening

Current, Symptomatic Medicine

Preventive Medicine

Early Diagnosis

Preventive Treatment



The NanoMedicine Research Agenda1. Nanodiagnostics: early and accurate tests

- biosensors, miniaturized devices which handle nano samples- targeted imaging agents to highlight pockets of disease

2. Targeted Drug Delivery: on the spot- bring the drug to the target site and monitor its impact

3. Regenerative Medicine: stimulated repair- help the body to (re)build organs or systems

For the main diseases in the world:Cancer, cardiovascular disease, musculo-skeletal, mental and

infectious disease, and diabetesKeratinocyte on a microperforated membrane, pore size 60 micronsFidia Advanced BiopolymersAlessandra Pavesio

Courtesy of Sam Wickline, Greg Lanza, WashU St Louis



Key Policy Issues

1. Regulatory: Imaging agents are approved as if they are drugs for treatment – too long and too costly

2. Adoption rate in Healthcare of new technologies is very slow – proper incentives needed

3. Limited Venture Capital expertise and availability

4. Intellectual Property legislation fragmented across Europe, and

• Different models in converging industries

5. Risk of negative public perception of “Nano”



Acknowledgement

Thanks to the Team: ~150 members of the ETP NanoMedicine, and especially:

Patrick Boisseau Uta FaureMike Eaton Oliver PanzerAlessandra PavesioKlaus Michael WeltringMaaike van VelzenSebastian SchmittKarl-Jurgen Schmidt

european technology platform nanomedicine 106/12/2006 paul smit, philips paul smit november 2006

Documents